BREAKING
Reading International, Inc. (RDI) Reports Q4 Earnings 24 minutes ago Sunrun Inc. (RUN) Jumps 7.6% to $13.06 42 minutes ago IMUNON 2025 Financial Review 48 minutes ago BIO-key International, Inc. (BKYI) Reports Q4 Earnings 2 hours ago SiTime Corporation (SITM) Jumps 8.9% to $339.00 2 hours ago Purple Innovation, Inc. (PRPL) Reports Q4 Earnings 2 hours ago TON Strategy Company (VERB) Reports FY2025 Earnings 2 hours ago Allarity Therapeutics, Inc. (ALLR) Reports FY2025 Earnings 3 hours ago McCormick & Company, Incorporated (MKC) Q1 2026 Earnings Recap 3 hours ago J.Jill, Inc. (JILL) Q4 Earnings: Misses on EPS, Revenue Recap 3 hours ago Reading International, Inc. (RDI) Reports Q4 Earnings 24 minutes ago Sunrun Inc. (RUN) Jumps 7.6% to $13.06 42 minutes ago IMUNON 2025 Financial Review 48 minutes ago BIO-key International, Inc. (BKYI) Reports Q4 Earnings 2 hours ago SiTime Corporation (SITM) Jumps 8.9% to $339.00 2 hours ago Purple Innovation, Inc. (PRPL) Reports Q4 Earnings 2 hours ago TON Strategy Company (VERB) Reports FY2025 Earnings 2 hours ago Allarity Therapeutics, Inc. (ALLR) Reports FY2025 Earnings 3 hours ago McCormick & Company, Incorporated (MKC) Q1 2026 Earnings Recap 3 hours ago J.Jill, Inc. (JILL) Q4 Earnings: Misses on EPS, Revenue Recap 3 hours ago
ADVERTISEMENT
LLY

Eli Lilly and Company

$LLY NYSE Mar 31, 2026 BMO FY 2026

Investor Toolbox

Listen to Call

Recording not yet available.

Read Transcript

Transcript not yet available.

View Infographic

Infographic not yet available.

Earnings History

View past quarters and earnings trends.

View History

LLY Coverage

Event Eli Lilly and Company (LLY) Phase 3b data presented at AAD Annual Meeting show Lilly’s Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity Mar 29, 2026 Event Eli Lilly and Company (LLY) Lilly’s EBGLYSS (Lebrikizumab-Lbkz) Delivered Up To Four Years Of Durable Disease Control For Patients With Moderate-To-Severe Atopic Dermatitis Mar 27, 2026 Event Eli Lilly and Company (LLY) Lilly’s triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes Mar 19, 2026 Transcript Eli Lilly and Company (LLY) Q4 2025 Earnings Call Transcript Mar 10, 2026 News Eli Lilly and Company (LLY) Surges 5.1% — Developing Story Feb 23, 2026 News Eli Lilly and Company (LLY) to acquire Orna Therapeutics Feb 9, 2026 News Key highlights from Eli Lilly’s (LLY) Q4 2025 earnings results Feb 4, 2026 Transcript Eli Lilly and Company (LLY) Q2 2025 Earnings Call Transcript Jan 22, 2026